 "Pharma Stocks, Sun Pharma, Cadila, Cipla")
Shares of Shilpa Medicare have surged by 13% to Rs 434 per share on the BSE in morning trade after the company said that it has received Establishment Inspection Report (EIR) from the US health regulator for both of its facilities located at Raichur, Karnataka.
“Our both active pharmaceutical ingredient (API) manufacturing facilities located at Raichur, Karnataka, received EIR from the US Food and Drug Administration (US FDA),” Shilpa Medicare said in a regulatory filing.
This inspection was carried out between 16th and 19th January, 2018. The inspection has now been closed by USFDA, it added.
On
“Our both active pharmaceutical ingredient (API) manufacturing facilities located at Raichur, Karnataka, received EIR from the US Food and Drug Administration (US FDA),” Shilpa Medicare said in a regulatory filing.
This inspection was carried out between 16th and 19th January, 2018. The inspection has now been closed by USFDA, it added.
On
